natgillin/translations-raw huggingface dataset:
If you forget to take Nifedipine Pharmamatch retard If you have forgotten to take Nifedipine Pharmamatch retard, then do so as soon as possible.
Če ste pozabili vzeti zdravilo Nifedipine Pharmamatch retard Če ste pozabili vzeti zdravilo Nifedipine Pharmamatch retard, to storite čimprej.
In dialysis patients with malignant hypertension and hypovolaemia, a marked decrease in blood pressure can occur.
Pri bolnikih na dializi z maligno hipertenzijo in hipovolemijo lahko pride do izrazitega znižanja krvnega tlaka.
The primary end-point was the combination of stroke, MI (including sudden death), heart failure or death from any other cardiovascular cause (composite end-point).
Primarni opazovani dogodek je bila kombinacija infarkta, miokardnega infarkta (vključno z nenadno smrtjo), srčne odpovedi ali smrti s katerimkoli srčno-žilnim vzrokom (sestavljeni opazovani dogodek).
It is a fact that there are nifedipine products on the EU market which are not contraindicated neither in pregnancy nor in women capable of child bearing.
Dejstvo je, da so na trgu zdravila, ki vsebujejo nifedipine in niso kontraindicirana niti v nosečnosti, niti pri ženskah v rodni dobi.
It is recommended to take the tablets in the morning with a glass of water (not grapefruit juice).
Priporočljivo je, da tablete vzamete zjutraj s kozarcem vode (brez grenivkinega soka).
Nifedipine Pharmamatch retard should neither be prescribed to patients with Kock pouch (ileostomy after proctocolectomy).
Zdravila Nifedipine Pharmamatch retard ne smemo predpisati bolnikom s "Kock pouch" (ileostomijo po proktokolektomiji).
Pharmamatch BV, Stationsweg Oost 281-D, 3931 ER Woudenberg, The Netherlands
Pharmamatch BV, Stationsweg Oost 281-D, 3931 ER Woudenberg, Nizozemska
However, the CHMP does not find it justified to contraindicate use in nursing mothers.
Kljub temu pa CHMP ne vidi dovolj dokazov za kontraindicirano uporabo pri doječih materah.
ATC code: C08CA05
Farmakoterapevtska skupina: Zaviralci kalcijevih kanalčkov, Oznaka ATC: C08CA05
Do not use Nifedipine Pharmamatch retard after the expiry date which is stated on the label carton after “Expiry date” or “exp.”.
Zdravila Nifedipine Pharmamatch retard ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake »Expiry date« ali »exp.«.
If necessary, the nifedipine dosage should be reduced (see also subsection ‘Effects of Nifedipine Pharmamatch retard on other active substances').
Po potrebi odmerek nifedipina znižamo (glejte tudi razdelek »Učinki zdravila Nifedipine Pharmamatch retard na druge zdravilne učinkovine«).
Co-administration of nifedipine with 100 mg acetylsalicylic acid does not alter the effect of acetylsalicylic acid on platelet aggregation or bleeding time.
Sočasno uporaba nifedipina in 100 mg acetilsalicilne kisline ne spremeni učinka acetilsalicilne kisline na agregacijo trombocitov in trajanje krvavitve.
Due to inhibition of the CYP3A4 system, cimetidine increases the plasma concentration of nifedipine, and therefore the antihypertensive effect of nifedipine may be potentiated.
Zaradi zaviranja sistema CYP3A4 cimetidin zviša plazemsko koncentracijo nifedipina in s tem zveča antihipertenzijski učinek nifedipina.
- The active substance is nifedipine.
- Zdravilna učinkovina je nifedipin.
exfoliative dermatitis, Steven-Johnsons syndrome, erythema multifome, urticaria, fixed drug eruption, pemphigus, phototoxicity.
eksfoliativni dermatitis, Stevens-Johnsonov sindrom, multiformni eritem, urtikarija, fiksirane erupcije zaradi zdravil, pemfigus, fototoksičnost
Your doctor will determine the duration of treatment.
Trajanje zdravljenja določi vaš zdravnik.
Co-administration of nifedipine with 100 mg acetylsalicylic acid, benazepril, candesartancilexetil, doxasozine, omeprazole, orlistat, pantoprazole, ranitidine, rosiglitazone or triamterene/hydrochlorothiazide does not affect the pharmacokinetics of nifedipine.
Sočasna uporaba nifedipina in 100 mg acetilsalicilne kisline, benzaprila, kandesartancileksetila, doksazosina, omeprazola, orlistata, pantoprazola, ranitidina, roziglitazona ali triamteren/hidroklorotiazida ne vpliva na farmakokinetiko nifedipina.
Symptomatic treatment of chronic stable angina pectoris as monotherapy or in combination with a beta-blocker.
Simptomatsko zdravljenje kronične stabilne angine pektoris v monoterapiji ali kombinaciji z zaviralci adrenergičnih receptorjev beta.
- Nifedipine Pharmamatch retard is used to treat high blood pressure (hypertension).
- Zdravilo Nifedipine Pharmamatch retard se uporablja za zdravljenje visokega krvnega tlaka (hipertenzije).
In patients with diarrhoea, the residence time of the tablet in the gastrointestinal tract, and as a result thereof, the duration of action are decreased.
Pri bolnikih z drisko se skrajša zadrževalni čas tablete v gastrointestinalnem traktu in s tem tudi trajanje delovanja zdravila.
The pharmacokinetic properties of nifedipine in the Nifedipine Pharmamatch retard tablet are linear in a dose range of 30-180 mg. Based on the results of the bioequivalence studies, Nifedipine Pharmamatch retard tablets 30 mg and 60 mg can be considered to be bioequivalent to the reference product Adalat OROS under fasting and fed conditions.
Farmakokinetične lastnosti nifedipina v zdravilu Nifedipine Pharmamatch retard tablete so premo sorazmerne v območju odmerkov 30-180 mg. Na podlagi rezultatov bioekvivalenčnih študij lahko Nifedipine Pharmamatch retard tablete 30 mg in 60 mg štejemo za bioekvivalentnega referenčnemu zdravilu Adalat OROS pri teščih in neteščih bolnikih.
Therefore, Nifedipine Pharmamatch retard is effective in angina pectoris and hypertension.
Zato je Nifedipine Pharmamatch retard učinkovito zdravilo pri angini pektoris in hipertenziji.
Like all medicines, Nifedipine Pharmamatch retard can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Nifedipine Pharmamatch retard neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Therefore, a decrease or an increase in nifedipine plasma concentrations and hence an alteration in efficacy cannot be excluded.
Zato ne moremo izključiti zvišanja oz. znižanja plazemskih koncentracij nifedipina ter s tem povezane spremembe učinkovitosti.
Endocrine disorders: - Rare:
Bolezni endokrinega sistema: - Redki:
It is recommended to take the Nifedipine Pharmamatch tablets in the morning with a glass of water (not grapefruit juice).
Najbolje je, če tablete Nifedipine Pharmamatch vzamete zjutraj s kozarcem vode (brez grenivkinega soka).
If necessary, your doctor can increase the dosage to 90 mg once-daily.
Po potrebi lahko vaš zdravnik zviša odmerek na 90 mg enkrat dnevno.
Since it has been demonstrated that Nifedipine Pharmamatch retard tablets are bioequivalent with the nifedipine containing product Adalat OROS tablets, the Nifedipine Pharmamatch retard tablets are interchangeable with Adalat OROS tablets at all times.
Ker so dokazali, da so Nifedipine Pharmamatch retard tablete bioekvivalenten zdravilu Adalat OROS tablete, ki vsebuje nifedipin, so Nifedipine Pharmamatch retard tablete v vsakem primeru zamenljive s tabletami Adalat OROS.
In severe cases, a lowering of the dose can be necessary.
V hudih primerih je treba odmerek zmanjšati.
If you take more Nifedipine Pharmamatch retard than you should If you take more Nifedipine Pharmamatch retard than you should, immediately contact your doctor or pharmacist.
Če ste vzeli večji odmerek zdravila Nifedipine Pharmamatch retard, kot bi smeli Če ste vzeli večji odmerek zdravila Nifedipine Pharmamatch retard, kot bi smeli, nemudoma obvestite svojega zdravnika ali farmacevta.
As a result of the relaxation of arterial muscle, nifedipine reduces peripheral resistance, leading to an improvement of peripheral blood flow whilst decreasing after-load.
Posledica relaksacije mišic arterij je zmanjšanje perifernega žilnega upora, kar izboljša periferni krvni pretok in zmanjša breme (afterload).
Metabolic disturbances include hyperglycaemia, metabolic acidosis and hypo- or hyperkalaemia.
- Presnovne motnje vključujejo hiperglikemijo, presnovno acidozo in hipo- ali hiperkaliemijo.
atrophic endometrium.
atrofični endometrij
Symptoms of obstruction have also been seen in patients in which no gastrointestinal narrowing was diagnosed.
O simptomih obstrukcije so poročali tudi bolniki brez diagnoze zoženja v prebavnih poteh.
Upon co-administration with rifampicin, the bioavailability of nifedipine is markedly reduced (95% decrease of AUC) and thus its efficacy weakened.
Pri sočasni uporabi skupaj z rifampicinom se biološka uporabnost nifedipina močno zmanjša (95-% zmanjšanje AUC) in s tem tudi učinkovitost.
If you are on kidney dialysis please consult your doctor before taking this medicine.
Če ste dializni bolnik, se posvetujte z vašim zdravnikom preden boste vzeli to zdravilo.
Taking Nifedipine Pharmamatch retard with food and drink The blood pressure lowering effect of nifedipine can be enhanced due to the intake of grapefruit juice.
Jemanje zdravila Nifedipine Pharmamatch retard skupaj s hrano in pijačo Učinek nifedipina na zniževanje krvnega tlaka se lahko poveča pri zaužitju grenivkinega soka.
ventricular arrhythmias, conduction disturbances, exacerbation of supraventricular arrhythmias, digital blood flow reduction in patients with Raynaud's syndrome.
prekatne aritmije, prevodne motnje, poslabšanje supraventrikularnih aritmij, zmanjšanje pretoka krvi v prste pri bolnikih z Raynaudovim sindromom
Simultaneous administration of quinupristin/dalfopristin and nifedipine may lead to increased plasma concentrations of nifedipine (Cmax increase of 33% compared to placebo).
Zaradi sočasnega dajanja kombinacije kinupristin/dalfopristin in nifedipina se lahko zvišajo plazemske koncentracije nifedipina (zvišanje Cmax za 33 % v primerjavi s placebom).
Nifedipine can worsen an existing decompensatio cordis.
Nifedipin lahko poslabša obstoječo dekompenzacijo srca.
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARIES OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA
DODATEK II ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA DOPOLNILO POVZETKOV GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJE IN NAVODILA ZA UPORABO, PREDSTAVLJENI S STRANI EVROPSKE AGENCIJE ZA ZDRAVILA
Some studies reveal increased plasma concentrations of nifedipine in case of co-administration with quinidine, though others revealed no effects on the pharmacokinetic properties of nifedipine.
V nekaterih študijah so odkrili zvišanje plazemske koncentracije nifedipina pri sočasni uporabi nifedipina in kinidina, v drugih pa učinkov na farmakokinetične lastnosti nifedipina niso dokazali.
Some of these substances, like fluoxetine, indinavir and ritonavir, have been demonstrated to inhibit the CYP3A4 mediated metabolism of nifedipine in vitro.
Za nekatere od teh zdravilnih učinkovin, kot na primer fluoksetin, indinavir in ritonavir, so dokazali, da in vitro zavirajo presnovo nifedipina, posredovano s CYP3A4.
- Very rare:
- Zelo redki:
Increased or decreased heart rates are also a symptom of overdosage.
Simptoma prekomernega odmerjanje sta tudi pospešeno ali upočasnjeno utripanje srca.
dizziness, tiredness.
omotica, utrujenost
Diltiazem decreases the clearance of nifedipine.
Diltiazem zmanjša očistek nifedipina.
What Nifedipine Pharmamatch retard is and what it is used for Before you take Nifedipine Pharmamatch retard How to take Nifedipine Pharmamatch retard Possible side effects
Kaj je zdravilo Nifedipine Pharmamatch retard in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Nifedipine Pharmamatch retard Kako jemati zdravilo Nifedipine Pharmamatch retard Možni neželeni učinki
Nifedipine Pharmamatch retard may be used alone, or in combination with a medicine from another group of medicines called β-blockers.
Zdravilo Nifedipine Pharmamatch retard se lahko uporablja samo ali pa v kombinaciji z zdravilom iz druge skupine, ki ji pravimo zaviralci beta.
Nifedipine can further lower the blood pressure.
Nifedipin lahko dodatno zniža krvni tlak.
In case of co-administration of nifedipine with β-blocking medicines, the patient should be carefully monitored, since severe hypotension can occur.
V primeru hkratnega dajanja nifedipina in zaviralca beta je treba bolnika skrbno spremljati, ker lahko pride do hude hipotenzije.
Nifedipine can lower the chance of conception.
Nifedipin lahko zmanjša možnost zanositve.
- Nifedipine Pharmamatch retard is used to reduce the frequency of occurence of a tight, painful chest ache caused by a shortage of oxygen in the heart muscle (angina pectoris).
- Zdravilo Nifedipine Pharmamatch retard se uporablja za zmanjšanje pojavnosti močnih bolečin v prsih, ki jih povzroča pomanjkanje kisika v srcu (angina pektoris).
angina upon abrupt withdrawal of nifedipine, increased frequency or worsening of angina, aggravation of myocardial ischemia including myocardial infarction, palpitations (tachycardia - accelerated pulse rate), congestive heart failure, hypotension, orthostatic hypotension.
angina po hitri odtegnitvi nifedipina, zvišana pogostnost ali poslabšanje angine, poslabšanje miokardne ishemije (vključno z miokardnim infarktom), palpitacije (tahikardija - pospešeno utripanje srca), srčno popuščanje, hipotenzija, ortostatska hipotenzija
If the dose of nifedipine is increased during co-administration of both medicines, a reduction of the nifedipine dose should be considered when the treatment with phenytoin is discontinued.
Če odmerek nifedipina med sočasno uporabo obeh zdravil zvišamo, je treba preučiti možnosti znižanja odmerka nifedipina po prekinitvi zdravljenja s fenitoinom.
Nifedipine is excreted into breast milk in small amounts.
Nifedipin se v majhnih količinah izloča v materino mleko.
Additional fluids should be administered with caution to avoid cardiac overload.
Dodatne tekočine je treba dajati previdno, ker se lahko pojavi preobremenitev srca.
Erythromycin, fluoxetine, protease-inhibitors and azole-derivatives No clinical interaction studies have been performed between nifedipine and active substances that inhibit the CYP3A4 system, like erythromycin, fluoxetine, protease-inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir) and azole-derivatives (ketoconazole, itraconazole and fluconazole).
Eritromicin, fluoksetin, zaviralci proteaze in derivati azolov Kliničnih študij medsebojnega delovanja med nifedipinom in zdravilnimi učinkovinami, ki zavirajo sistem CYP3A4, kot so eritromicin, fluoksetin, zaviralci proteaze (amprenavir, indinavir, nelfinavir, ritonavir, sakvinavir) in derivati azolov (ketokonazol, itrakonazol in flukonazol), niso izvedli.
In those men who are repeatedly unsuccessful in fathering a child by in vitro fertilisation, and where no other explanation can be found, calcium antagonists like nifedipine should be considered as possible causes.
Pri moških, kjer ni mogoče pojasniti večkratne neuspešne oploditve v postopkih oploditve in vitro, je treba kot možne vzroke obravnavati antagoniste kalcijevih kanalčkov, med katere spada nifedipin.
Patients who are receiving kidney dialysis and have a very high blood pressure and low blood volume might experience a sudden drop in their blood pressure when they take Nifedipine Pharmamatch retard.
Pri bolnikih na dializi z zelo visokim krvnim tlakom in majhnim volumnom krvi lahko pride do nenadnega padca krvnega tlaka, ko vzamejo zdravilo Nifedipine Pharmamatch retard.
In such an event, you should stop taking Nifedipine Pharmamatch retard and contact your doctor.
V tem primeru prenehajte jemati zdravilo Nifedipine Pharmamatch retard in obvestite svojega zdravnika.
Upon co-administration with phenytoin, the bioavailability of nifedipine is reduced (70% decrease of AUC) and thus its efficacy weakened.
Pri sočasni uporabi skupaj s fenitoinom se biološka uporabnost nifedipina zmanjša (70-% zmanjšanje AUC) in s tem tudi učinkovitost.
The recommended initial dose is one 30mg tablet once-daily.
Priporočeni začetni odmerek je ena 30 mg tableta enkrat dnevno.
The two main metabolites are the pyridine-3-carbonic acid metabolite and a 2-hydroxymethylpyridine-3-carbonic acid metabolite or, depending on the pH, its lacton form.
Njegova poglavitna presnovka sta piridin-3-karbonska kislina in hidroksimetilpiridin-3-karbonska kislina ali njegova laktonska oblika (odvisno od pH-vrednosti).
Coadministered of the mentioned medicines with nifedipine can be expected to lead to a substantial increase in bioavailability of nifedipine, due to a decreased first pass metabolism and decreased elimination.
Pričakujemo, da sočasna uporaba omenjenih zdravil in nifedipina povzroči znatno zvišanje biološke uporabnosti nifedipina zaradi zmanjšane presnove prvega prehoda in zmanjšanega izločanja.
Neozipine XL 30/60 mg 30 mg / 60 mg prolonged-release tablets
Neozipine XL 30/60 mg 30 mg / 60 mg Tableta s podaljšanim sproščanjem
You should not use Nifedipine Pharmamatch retard for secondary prevention of a heart attack.
Zdravila Nifedipine Pharmamatch retard ne smete uporabiti za sekundarno preprečevanje srčnega infarkta.
In a clinical study, the effect of Nifedipine retard prolonged-release tablets on cardiovascular and cerebrovascular morbidity was studied.
Učinke zdravila Nifedipine retard tablete s podaljšanim sproščanjem na srčno-žilno in cerebrovaskularno smrtnost so preučili v klinični študiji.
Take special care with Nifedipine Pharmamatch retard - if you suffer from decreased blood flow to the fingers and/or toes, caused by a narrowing of the veins (ischemia).
Bodite posebno pozorni pri jemanju zdravila Nifedipine Pharmamatch retard - Če imate zmanjšan pretok krvi v prste na rokah in/ali prste na nogah, ki je posledica zoženja ven
Elimination of the active substance and the restoration of stable cardiovascular conditions have priority.
Prednost imata odstranitev zdravilne učinkovine in obnovitev stabilnega srčno-žilnega stanja.
Nifedipine can worsen the decreased blood flow.
Nifedipin lahko poslabša zmanjšan pretok krvi.
After oral ingestion, gastric lavage is indicated, if necessary in combination with irrigation of the small intestine.
Pri peroralnem zaužitju je indicirana gastrična lavaža, po potrebi v kombinaciji z izpiranjem tankega črevesja.
What Nifedipine Pharmamatch retard looks like and contents of the pack Nifedipine Pharmamatch retard are prolonged-release tablets, which appear as round, biconvex tablets with a pale red colour.
Izgled zdravila Nifedipine Pharmamatch retard in vsebina pakiranja Nifedipine Pharmamatch retard so tablete s podaljšanim sproščanjem, ki so okrogle, izbočene na obeh straneh in bledo rdeče barve.
Diabetic patients taking Nifedipine Pharmamatch retard may require adjustment of their control.
Bolnikom s sladkorno boleznijo, ki jemljejo zdravilo Nifedipine Pharmamatch retard, je morda treba prilagoditi kontrolne meritve.
WHAT NIFEDIPINE PHARMAMATCH RETARD IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO NIFEDIPINE PHARMAMATCH RETARD IN ZA KAJ GA UPORABLJAMO
In studies in mice, rats and rabbits, a dose which was maternally toxic induced teratogenic effects in some cases and embryotoxicity.
V raziskavah na miših, podganah in kuncih so odmerki, toksični za mater, inducirali teratogene učinke in v posameznih primerih toksičnost za zarodek.
Pharmamatch BV Stationsweg Oost 281D 3930 EB Woudenberg The Netherlands
Pharmamatch BV Stationsweg Oost 281D 3930 EB Woudenberg Nizozemska
Nifedipine is not recommended for use in children and adolescents due to insufficient data on safety and efficacy.
Zaradi nezadostnih podatkov o varnosti in učinkovitosti uporaba nifedipina pri otrocih in mladostnikih ni priporočljiva.
Blood and lymphatic system disorders: - Very rare:
Bolezni krvi in limfatičnega sistema: - Zelo redki:
bezoars, gingival hyperplasia after long-term treatment, which recedes completely at discontinuation of nifedipine.
bezoarji, gingivalna hiperplazija po dolgotrajnem zdravljenju, ki popolnoma izzveni po prekinitvi jemanja nifedipina
paresthesia of the extremities (arms and legs), finger twitching.
parestezija okončin (rok in nog), trzanje prstov
In single cases of in vitro fertilisation calcium antagonists like nifedipine have been associated with reversible biochemical changes in the spermatozoa's head section that may result in impaired sperm function.
V posameznih primerih oploditve in vitro so ugotovili povezavo med antagonisti kalcijevih kanalčkov, kot je nifedipin, in reverzibilnimi spremembami glav semenčic, ki so lahko povzročile okvaro funkcije sperme.
In vitro fertilisation
Oploditev in vitro
Nifedipine can cause dizziness, headache, fatigue or nausea, especially at the beginning of therapy, after a change in your medication or when consumed with alcohol.
Vpliv na sposobnost upravljanja vozil in strojev Nifedipin lahko povzroči omotico, glavobol, utrujenost ali slabost, zlasti na začetku zdravljenja, pri prehodu iz enega zdravila na drugo ali v primeru uživanja skupaj z alkoholom.
Cardiovascular disorders:
Srčno-žilne bolezni:
aplastic anaemia, increase in serum potassium when nifedipine is combined with propranolol.
aplastična anemija, zvišanje serumskih ravni kalija pri sočasnem jemanju nifedipina in propranolola
- Rare:
- Redki:
As a consequence, the blood pressure lowering effect of nifedipine may be increased.
Posledično se lahko poveča učinek nifedipina na znižanje krvnega tlaka.
Renal impairment: Patients with renal impairment should not require adjustment of dosage.
Bolniki z ledvično okvaro: Pri bolnikih z ledvično okvaro ni treba prilagajati odmerka.
The blood pressure lowering effect of nifedipine can be induced in case of co-administration with other antihypertensive medicines.
Učinek nifedipina na zniževanje krvnega tlaka lahko induciramo s hkratnim dajanjem drugih antihipertenzivnih zdravil.
Medicines that do not influence Nifedipine Pharmamatch retard or are not influenced by Nifedipine Pharmamatch retard.
Zdravila, ki ne vplivajo na zdravilo Nifedipine Pharmamatch retard, ter zdravila, na katera zdravilo Nifedipine Pharmamatch retard ne vpliva
Patients switched from other calcium antagonists should initiate therapy at the recommended initial dose of 30mg Nifedipine Pharmamatch retard once-daily.
Pri bolnikih, ki menjajo zdravljenje in so prej jemali druge antagoniste kalcijevih kanalčkov, je priporočeni začetni odmerek 30 mg zdravila Nifedipine Pharmamatch retard enkrat dnevno.
Tacrolimus has been shown to be metabolised via the cytochrome P450 3A4 system.
Dokazano je, da se takrolimus presnavlja preko sistema citokroma P450 3A4.
4.4 Special warnings and special precautions for use In exceptional cases, the use of nifedipine can lead to severe complaints of angina pectoris, probably due to fast resorption and an overly abrupt decrease in blood pressure.
V izjemnih primerih lahko jemanje nifedipina povzroči hude napade angine pektoris, verjetno zaradi hitre resorpcije in preveč hitrega znižanja krvnega tlaka.
Steady-state concentrations are already reached after administration of the second Nifedipine Pharmamatch retard tablet.
Koncentracije v stanju dinamičnega ravnovesja se vzpostavijo že po zaužitju druge tablete zdravila Nifedipine Pharmamatch retard.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS STRIPS
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Studies in animals have shown reproductive toxicity, consisting of embryotoxicity and teratogenic effects at maternally toxic doses.
Študije na živalih so pokazale vpliv na sposobnost razmnoževanja, ki pri odmerkih, toksičnih za mater, obsega toksičnost za zarodek in teratogene učinke.
If necessary, adjustment of the quinidine dosage is recommended when treatment with nifedipine is started or ceased during treatment with quinidine (see also subsection ‘Interactions of other medicines with Nifedipine Pharmamatch retard').
Če se med zdravljenjem s kinidinom uvede ali prekine jemanje nifedipina, je priporočljiva prilagoditev odmerka kinidina (glejte tudi razdelek »Medsebojno delovanje zdravila Nifedipine Pharmamatch retard z drugimi zdravili«).
- if you use other medicines for high blood pressure, since these medicines may increase the effect of Nifedipine Pharmamatch retard on blood pressure.
- Če jemljete druga zdravila za visok krvni tlak, saj lahko ta zdravila povečajo učinek zdravila